evaluable after BV treatment due to progressive disease and death. Table 2 summarizes the median and range of bone marrow blast percentage in the nine patients before and after BV. Anti-VEGF therapy with BV did not have any significant effect on blast cell infiltration.
In contrast, the level of VEGF expression in the bone marrow significantly decreased during treatment with BV as shown in Table 2 and Figure 1a and b (before BV treatment: median 3.78 (arbitrary units) AU, range 1.5-5.8 AU; after BV treatment: median 2.57 AU, range 1.3-5.0 AU; Wilcoxon test; P ¼ 0.042). However, there was no significant change in VEGFR2 and p-VEGFR2 (Y951 and Y996) expression in the bone marrow, suggesting that phosphorylation at the two different sites of VEGFR2 were not inhibited by BV (see Table 2 ). Furthermore, MVD was not influenced by BV administration, and neither plasma VEGF (measured by ELISA) nor cellular VEGFR2, CECs or CEPCs (measured by flow cytometry) changed significantly (see Table 2 ).
Together, our data demonstrate that the antiangiogenic agent BV had a significant effect on the decrease in cellular VEGF expression in the bone marrow after 1-3 cycles BV without displaying any significant antileukemic activity in this heavily pretreated group and any significant effects on surrogate markers of the antiangiogenic response.
However, BV was well tolerated with a favorable safety profile. In our cohort three patients suffered from pre-existing grade 2 hypertension, and their blood pressure was controlled with escalation of antihypertensive medication (calcium-channel blockers, angiotensin-converting-enzyme inhibitors and diuretics). There were no hypertensive crisis or deaths related to hypertension in this patient cohort. No venous or arterial thromboembolic events, and no bleeding despite low platelet counts or proteinuria was seen. Therefore, our data should not discourage the initiation of studies investigating the potential of combining antiangiogenic treatment strategies with conventional cytotoxic drug regimens. A pilot study exploring this approach has shown promising CR rates in combination with cytarabine and mitoxantrone. 7 Further studies are necessary to define its exact role. For several years chronic lymphocytic leukemia (CLL) has been considered a disease of accumulation of relentless maturelooking malignant monoclonal B cells due to a presumed defect in programmed cell death. However, several observations suggest that CLL cells are not immortal and that they require signals from the microenvironment to maintain viability. Increasing evidence shows that neovascularization plays a role in the biology of CLL. 1 Increased microvessel density in marrow Letters to the Editor and lymph node and increased levels of certain pro-angiogenetic factors in the blood and urine of CLL patients were observed. 2 Ang-2 has a pivotal role in the disruption of stability and quiescence of mature vasculature that coincides with the reinitiation of vascular remodelling and angiogenic sprouting in adult, as occurs in tumors. Abnormal serum levels of angiopoietin-2 (Ang-2) were found in several hematological malignancies. 3, 4 The report of Hü ttmann et al., 5 recently published in Leukemia, described an increase of Ang-2 plasma levels in the ZAP-70 þ CD38 þ as compared to the ZAP-70 À CD38 À CLL patients. Moreover, Ang-2 plasma levels detected in Binet B and C patients exceeded those of Binet stage A cases, suggesting a correlation between Ang-2 secretion and CLL progression. Exploratory experiments of gene expression profiling (GEP) were previously performed in our laboratory on 29 unpurified CLL samples (% CD5 þ CD19 þ cells, 8279%) (data deposited in NCBIs Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/ geo/, Accession:GSE4207) with Agilent Human-1A-OligoMicroarray comprising 20 173 (60-mer) oligonucleotide probes using the protocol described elsewhere. 6 Among the differentially expressed genes between 14 Ig-mutated CLL (M-CLL) and 15 Ig-unmutated CLL (UM-CLL) subsets, Ang-2 was found as one of the most up-regulated genes in UM-CLL relative to M-CLL (P ¼ 3.02 Â 10 À6 , ANOVA). These results prompted us to undertake a survey of our own CLL patients to examine further the relationship between Ang-2 expression, immunoglobulin (Ig) mutational status and other established prognostic markers as well as progression-free survival.
We included 63 CLL patients (40 men, 23 women) in this study on the basis of the availability of peripheral blood (PB) at diagnosis with a high percentage of CD5 þ CD19 þ cells (8279%). The median age was 62 (range, 32-87) and the mean follow-up time was 3.8 years. Informed consent was provided according to the Declaration of Helsinki. IgV H gene sequence analysis was performed using the protocol of Marasca et al. 7 Peripheral blood mononuclear cells (PBMCs) were obtained from B-CLL patients by density gradient centrifugation. In 10 CLL cases and in 9 normal controls, the CD19 þ fraction was collected from peripheral blood using CD19Microbeads (Miltenyi Biotec, Auburn, CA, USA), obtaining a purity over 99%. Moreover, Ang-2 mRNA levels were measured by quantitative real-time PCR using SYBR Green reagents and an ABI Prism 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA), whereas Ang-2 protein expression was evaluated in the bone marrow (BM) of 10 CLL cases by immunohistochemistry using specific goat polyclonal antibodies (sc-7016; Santa Cruz Biotechnology, Inc., USA). Progressionfree survival functions have been estimated using the productlimit (Kaplan-Meier) method and the curves have been compared between groups using log-rank test.
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Ang-2 transcript levels were measured by real-time PCR in 63 CLL patients at diagnosis (29 CLL cases used in the previous GEP experiments and 34 further cases). We found that UM-CLL expressed higher levels of Ang-2 than did M-CLL (median, 38.61 vs 0.27) (Po0.0001), confirming the results obtained by GEP (Figure 1a ). Fourteen patients (22%) showed discordant results, with 10 M-CLL cases with high levels of Ang-2 and 4 UM-CLL cases with low expression, and we will refer to these patients as Ang-2 outliers. No bias in the percentage of CD5 þ CD19 þ cells between groups were detected. Comparing the 10 M-CLL Ang-2 outliers with the remaining 27 M-CLL, we observed a differential sex distribution, being male 8 out of 10 (80.0%) outlier patients, instead 12 out of 27 (44.4%) M-CLL cases with low Ang-2 expression (P ¼ 0.054). Moreover, higher white blood cell (P ¼ 0.047) and lower platelet counts (P ¼ 0.044) were found in M-Ang-2 outliers.
The median level of Ang-2 mRNA was 0.93 with a wide range of expression between 1 Â 10 À3 and 7.9 Â 10 5 . All CLL patients were divided into 2 subgroups (high Ang-2 and low Ang-2 groups) with a cut-off equal to median value. No bias in both percentage of CD5 þ CD19 þ cells and mean follow-up time between groups was detected. Noteworthy, we found that high expression of Ang-2, as measured at diagnosis, is associated with adverse clinical outcome in CLL patients (Table 1) . Increased levels of Ang-2 mRNA were measured along Binet stages (P ¼ 0.004), with Binet stage B and C patients expressing five-fold and eighty-fold higher Ang-2 in comparison to Binet stage A cases, respectively (Figure 1b) . Moreover, CLL with a percentage of CD38 þ cells over 30% showed a ten-fold higher median Ang-2 expression than CLL with CD38o30% (median, 4.58 vs 0.49, respectively; P ¼ 0.012) (Figure 1c) . Patients with unfavorable cytogenetics expressed higher levels of angiopoietin-2 than did patients with normal karyotype or deletion 13q (median, 5.5 vs 0.35) (P ¼ 0.037). Figure 2 shows the Kaplan-Meier progression-free survival (PFS) curves from diagnosis comparing high Ang-2 and low Ang-2 CLL subsets. Patients whose samples had high Ang-2 levels showed Table 1 Comparisons of molecular and clinical parameters between high Ang-2 CLL group (n ¼ 32) and low Ang-2 CLL group (n ¼ 31)
High Ang-2 CLL Low Ang-2 CLL P-value Progression-free survival curves based on Ang-2 expression. CLL patients (n ¼ 58) are divided into high-and low-expressing subsets based on the detection of more than 0.93 or less than 0.93 Ang-2 mRNA relative quantity. Median PFS for high Ang-2 CLL group: 21 months; median PFS for low Ang-2 CLL group: 146 months (P ¼ 0.002, log-rank test).
Letters to the Editor significantly shorter progression-free survival (median, 21 months) than patients whose samples at diagnosis had low Ang-2 levels (median, 146 months) (P ¼ 0.002). Then, Ang-2 levels were associated with sex (P ¼ 0.003), being male 26 out of 32 (81.3%) CLL patients with high levels of Ang-2. Finally, there was a trend toward higher percentage of circulating lymphocytes (P ¼ 0.053), lower platelet count (P ¼ 0.061) and higher serum level of b2-microglobulin (P ¼ 0.057) in patients expressing elevated Ang-2 (Table 1) .
In order to define the cellular population expressing Ang-2 in PB and BM, we purified CD19 þ and CD19 À fractions from PBMCs of 10 CLL patients (4 UM-CLL with high Ang-2 mRNA level and 6 M-CLL with low Ang-2 mRNA level, as previously assessed), selected for the availability of BM biopsies for immunohistochemical study. Leukemic CD19 þ cells displayed Ang-2 transcript levels concordant with the correspondent unpurified samples (both high and low expressing), whereas bystander CD19 À cells did not reveal appreciable expression of Ang-2 in all 10 cases (median, 0.68). These results together with the capacity of Ang-2 secretion into the culture supernatant observed in three CLL cases by Hü ttmann et al. provide evidence that Ang-2 is expressed by circulating leukemic cells and not by bystander not malignant cells. In addition, in the CLL marrow microenvironment, immunohistochemical staining for Ang-2 protein showed that infiltrating CLL cells from 6 mutated cases were all negative, whereas CLL cells from 4 unmutated cases were uniformly positive, confirming in BM the observed Ang-2 mRNA expression measured in the circulating CLL fraction ( Figure S1 ). Finally, we compared Ang-2 mRNA expression of CD19 þ purified cells from 10 CLL and from 9 normal controls. The results confirmed the abnormal expression of Ang-2 in UM-CLL subsets (median, normal control 4.6 vs UM-CLL 3146) and the low expression in M-CLL subset (median, M-CLL 0.072).
Our results regarding the adverse prognostic significance of high expression of Ang-2 by CLL cells are substantially in keeping with Hü ttmann et al. Importantly, in our series, CLL patients expressing at diagnosis high levels of Ang-2 usually had more advanced clinical stage and a higher percentage of CD38 þ cells, had unmutated immunoglobulin status and unfavorable cytogenetics and had a shorter progression-free survival. These associations support the idea of the involvement of Ang-2 in the mechanisms of CLL disease progression. In addition, both circulating and BM-infiltrating Ig-unmutated CLL B-cells are able to express higher levels of Ang-2 than Ig-mutated CLL and normal B cells, suggesting the presence of an intrinsic defect in Ang-2 expression that could be pathogenetically relevant in CLL marrow microenvironment and could be involved in the differential clinical behavior of Ig-mutated and Ig-unmutated CLL cases. R Maffei 1, 5 , R Marasca 1, 5 
